Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Luca Laurenti, Idanna Innocenti, Robin Foa, Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela RagoOsnat Bairey, Giovanni Tripepi, Kari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaEuropean Journal of Haematology
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • CLL-IPI
  • PFS
  • chemo-immunotherapy
  • chronic lymphocytic leukemia
  • prognosis
  • progression-free survival

Fingerprint

Entra nei temi di ricerca di 'Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment'. Insieme formano una fingerprint unica.

Cita questo